ECE2023 Eposter Presentations Pituitary and Neuroendocrinology (234 abstracts)
1Endocrinology Research Centre, Moscow, Russia; 2Endocrinologists, Participating Regions, Russia
Introduction: ADH-deficiency (central diabetes insipidus, ADH-D) is a rare disease, and data on worldwide and country-specific prevalence rates are scarce. ADH-D registries could provide valuable information on epidemiology, etiological distribution, treatment requirements and potentially serve as a guide for management decisions in clinical practice.
Objectives: To assess the epidemiological data on ADH-D in Russian Registry for Central Diabetes Insipidus (RCDI)
Materials and methods: Database of the Russian Registry for Central Diabetes Insipidus, which includes data from 42 regions. Date of analysis 10-Sep-2022.
Results: Since previously reported data in 2018, the number of patients has increased from 2004 to 2971 patients with different etiologies of ADH-D. Highest prevalence is seen in Moscow region 5.4 cases per 100 000 population. Male to female ratio: 1253(42.2%): 1718(57.8%), mean age at diagnosis 32.6 years. Among the identified etiologies the most common were postoperative (16%), pathology of development of hypothalamicpituitary region (9.3%), head trauma (6.6%), tumors (5.4%) and hereditary forms of ADH-D (4.3%). Rare forms of ADH-D with less than 4% overall were neuroinfection, Langergans cell hystiocytosis, sarcoidosis, Sheehan syndrome, DIDMOAD syndrome and hypophysitis. Idiopathic ADH-D was registered in 42% of patients. Data on current therapy was available in 2657 patients. Most of the patients receive oral desmopressin (n=1470, 55.3%), followed by sublingual (n=911, 34.3%) and intranasal (n=276, 10.4%) forms.
Conclusions: Russian Registry for Central Diabetes Insipidus is a promising instrument for the assessment of epidemiology and treatment modalities in a rare endocrine disorder. Further efforts are made to include all the regions of the country and improve the data quality.